Long-Term Survival and Clinical Stabilization in Mixed Gliomas using an Integrative Immunobiological Approach: A Two-Patient Case Report

Abstract

Background: Mixed and high-grade gliomas represent some of the most challenging primary malignancies of the central nervous system because of their infiltrative growth pattern, molecular heterogeneity, treatment resistance, and ability to adapt to therapeutic pressure. Despite advances in neurosurgery, radiotherapy, chemotherapy, and molecularly guided treatment, long-term disease control remains difficult to achieve in patients with aggressive glioma, particularly when recurrent or progressive disease is associated with extensive peritumoral edema, neurological dysfunction, or mass effect.

The biological behaviour of gliomas is increasingly understood to be influenced not only by the intrinsic characteristics of tumour cells but also by the tumour microenvironment. Interactions among malignant cells, immune cells, stromal components, cytokines, angiogenic pathways, and metabolic signals contribute to immune evasion, tumour progression, treatment resistance, and recurrence. Glioma cells can establish an immunosuppressive microenvironment that impairs effective anti-tumour immune responses, providing a rationale for therapeutic strategies aimed at restoring or enhancing host immune surveillance.

Immunobiological approaches have therefore attracted increasing interest as potential adjuncts to conventional cancer treatment. Strategies directed toward cellular immunity, antigen presentation, immune modulation, and the tumour microenvironment may theoretically complement cytotoxic or radiation-based therapies by targeting biological mechanisms that are not fully addressed by conventional treatment alone. Dendritic-cell-based approaches, cytokine and immune-modulating strategies, and other investigational immunological interventions have been explored in glioma, although their clinical efficacy remains an area of active investigation.

An integrative oncology model seeks to combine appropriately selected conventional treatment with supportive and investigational interventions directed at multiple biological processes, including immune regulation, inflammation, oxidative stress, tumour metabolism, angiogenesis, and tissue repair. The underlying concept is not to replace evidence-based oncological treatment, but to explore whether complementary biological interventions can be incorporated into an individualized therapeutic framework while maintaining continuous clinical and radiological surveillance.

Long-term clinical stabilisation in patients with aggressive glioma is particularly noteworthy when sustained disease control occurs despite radiologically complex lesions, treatment-related changes, recurrent neurological symptoms, or progressive-appearing abnormalities. Interpretation of such cases requires careful longitudinal assessment because treatment-related gliosis, radiation injury, necrosis, inflammatory changes, and viable tumour may produce overlapping clinical and radiological findings.

The present case describes prolonged survival and clinical stabilisation in a patient with a mixed/high-grade glioma managed over an extended period using an integrative immunobiological strategy incorporating conventional and investigational modalities. The case is presented primarily as a longitudinal clinical observation, with emphasis on the evolution of neurological status, imaging findings, treatment interventions, and periods of disease stability. The objective is to document the clinical course and generate hypotheses regarding the potential contribution of an integrated immunobiological approach to long-term disease control, while acknowledging that a single case cannot establish treatment efficacy or causality.

Case Presentation: This report presents two patients with GBM managed using an integrative therapeutic strategy involving dendritic cell vaccine therapy, sonodynamic therapy (SDT), Gc protein-derived macrophage activating factor (GcMAF), Super Transfer Factor (STF) injections, Mito Organo Peptide (MOP) thymus injections, Phyto molecular supplementation, and onco-nutrition support.

Case 1: A 52 years female patient diagnosed with GBM approximately 10 years prior,  declined surgical intervention and conventional chemo/radiotherapy. She underwent an integrative protocol consisting primarily of dendritic cell vaccines, SDT, GcMAF, STF injections, MOP thymus peptide therapy, phyto molecular medicines, and structured onco-nutritional therapy. The patient demonstrated prolonged survival with maintained neurological function and acceptable quality of life over long-term follow-up.

Case 2: A 36-year-old male diagnosed with GBM underwent surgical resection followed by radiotherapy and temozolomide (TMZ)-based chemotherapy. Subsequently, an integrative maintenance strategy using dendritic cell vaccine therapy, SDT, GcMAF, STF injections, MOP thymus peptide support, phytomolecular supplementation, and nutritional modulation was initiated. The patient remained clinically stable with preserved functional status during follow-up.

Conclusion: These cases highlight the potential translational relevance of integrative immunobiological approaches in GBM management. Although causal conclusions cannot be established from isolated observations, the prolonged stabilization and survival observed warrant further systematic investigation through controlled clinical studies.